UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

1135P - Sequential Combination of Low Dose Chemo-Modulating Temozolomide with Fotemustine in Metastatic Melanoma (MM). A Phase II Study

Annals of oncology, 2012-09, Vol.23, p.ix370-ix370

2012

Volltextzugriff (PDF)

19 THE IMPORTANCE OF A CAREFUL CARDIOLOGIC FOLLOW UP IN BREAST CANCER SURVIVORS: PRELIMINARY DATA OF AN OBSERVATIONAL STUDY

Cancer treatment reviews, 2010, Vol.36, p.S100-S100

2010

Volltextzugriff (PDF)

191PD_PR9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

2 cases of idiopathic thrombopenic purpura in pregnancy

Minerva ginecologica, 1982-01, Vol.34 (1-2), p.57

1982

Volltextzugriff (PDF)

250 CARDIOVASCULAR TOXICITY FOLLOWING SUNITINIB THERAPY IN METASTATIC RENAL CELL CANCER: A MULTICENTER RETROSPECTIVE ANALYSIS

European urology supplements : official journal of the European Association of Urology, 2009-03, Vol.8 (4), p.183-183

2009

Volltextzugriff (PDF)

2821 The phase III study INTERCEPTOR in locally advanced head and neck cancer (LA-HNC). Preliminary safety report

European journal of cancer (1990), 2015-09, Vol.51, p.S560-S560

2015

Volltextzugriff (PDF)

371PA MULTICENTER PHASE II TRIAL OF NAB-PACLITAXEL IN COMBINATION WITH CAPECITABINE IN PATIENTS (PTS) WITH HER-2 NEGATIVE AND TRIPLE NEGATIVE ADVANCED BREAST CANCER (ABC): AN INTERIM ANALYSIS

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv123-iv123

2014

Volltextzugriff (PDF)

41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial

Annals of oncology, 2021-05, Vol.32, p.S37

2021

Volltextzugriff (PDF)

6114 POSTER Clinical Outcomes of Bevacizumab (BV) + XELOX Combination for the First-line Treatment of Patients (pts) With Advanced Cancer of the Colon or Rectum (ACRC) – Preliminary Results of the OBELIX Study

European journal of cancer (1990), 2011, Vol.47, p.S426-S426

2011

Volltextzugriff (PDF)

6628 POSTER A Combination of RAD001 and Octreotide LAR as First-line Treatment of Well Differentiated Neuroendocrine Tumours – an I.T.M.O. (Italian Trials in Medical Oncology) Group Study

European journal of cancer (1990), 2011, Vol.47, p.S480-S480

2011

Volltextzugriff (PDF)

7117 Do circulating tumor cells (CTCs) correlate with response to first-line sunitinib in metastatic renal carcinoma?

European journal of cancer supplements, 2009, Vol.7 (2), p.428-428

2009

Volltextzugriff (PDF)

795 Protein Pathway Activation Mapping of KRAS Mutated NSCLC Clinical Samples Reveals Systemic Pathway Alterations and Point to New Therapeutic Targets for EGFR Resistant Tumors

European journal of cancer (1990), 2012-07, Vol.48, p.S189-S189

2012

Volltextzugriff (PDF)

800TiP Meet-URO 12: A randomized phase II trial of niraparib versus best supportive care (BSC) as maintenance treatment in patients with locally advanced or metastatic urothelial cancer (UC) whose disease did not progress after completion of first-line platinum-based chemotherapy

Annals of oncology, 2020-09, Vol.31, p.S607-S607

2020

Volltextzugriff (PDF)

837PPOOR RISK METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS ARE NOT A HOMOGENEOUS GROUP: A NEW STRATIFICATING MODEL IN THE ERA OF TARGETED THERAPY

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv291-iv291

2014

Volltextzugriff (PDF)

854P - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)

Annals of oncology, 2019-10, Vol.30, p.v333-v333

2019

Volltextzugriff (PDF)

854PUpdated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio

Annals of oncology, 2018-10, Vol.29, p.viii705-viii705

2018

Volltextzugriff (PDF)

Abstract P1-13-02: Withdrawn

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P1-P1-13-02

2018

Volltextzugriff (PDF)

Abstract P5-12-05: 9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P5-P5-12-05

2010

Volltextzugriff (PDF)

Advanced Oxidation Processes for Treating Groundwater Contaminated With TCE and PCE: Pilot-Scale Evaluations

Journal - American Water Works Association, 1988-05, Vol.80 (5), p.64-72

1988

Volltextzugriff (PDF)

Advanced oxidation processes for treating groundwater contaminated with TCE and PCE: pilot-scale evaluations

Journal of the American Water Resources Association, 1988-01, Vol.80 (5), p.64-72

1988

Volltextzugriff (PDF)

Advances in Hybrid Organic-Inorganic Proton Exchange Polymer Membranes Incorporating Heteropoly Acids

ECS transactions, 2007, Vol.11 (1), p.97-103

2007

Volltextzugriff (PDF)

Application of mass-transfer theory to the kinetics of a fast gas-liquid reaction: chlorine hydrolysis

Environmental science & technology, 1986-01, Vol.20 (1), p.44-50

1986

Volltextzugriff (PDF)

Applying infrared thermography as a quality-control tool for the rapid detection of polymer-electrolyte-membrane-fuel-cell catalyst-layer-thickness variations

Journal of power sources, 2012-08, Vol.211, p.4-11

2012

Volltextzugriff (PDF)

1 – 25 von 142

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(102)
Mit Volltextzugriff
(113)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(59)
Life Sciences & Biomedicine
(33)
Humans
(29)
Technology
(29)
Engineering
(28)
Physical Sciences
(27)
Exact Sciences And Technology
(25)
Applied Sciences
(23)
Female
(22)
Pollution
(20)
Water Treatment And Pollution
(19)
Adult
(18)
Drinking Water And Swimming-Pool Water. Desalination
(18)
Oncology
(18)
Water Resources
(17)
Engineering, Civil
(16)
Male
(15)
Research & Technology
(15)
Middle Aged
(14)
Water Treatment
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

1135P - Sequential Combination of Low Dose Chemo-Modulating Temozolomide with Fotemustine in Metastatic Melanoma (MM). A Phase II Study

19 THE IMPORTANCE OF A CAREFUL CARDIOLOGIC FOLLOW UP IN BREAST CANCER SURVIVORS: PRELIMINARY DATA OF AN OBSERVATIONAL STUDY

191PD_PR9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio

2 cases of idiopathic thrombopenic purpura in pregnancy

250 CARDIOVASCULAR TOXICITY FOLLOWING SUNITINIB THERAPY IN METASTATIC RENAL CELL CANCER: A MULTICENTER RETROSPECTIVE ANALYSIS

2821 The phase III study INTERCEPTOR in locally advanced head and neck cancer (LA-HNC). Preliminary safety report

371PA MULTICENTER PHASE II TRIAL OF NAB-PACLITAXEL IN COMBINATION WITH CAPECITABINE IN PATIENTS (PTS) WITH HER-2 NEGATIVE AND TRIPLE NEGATIVE ADVANCED BREAST CANCER (ABC): AN INTERIM ANALYSIS

41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial

421P Maintenance therapy with regorafenib (REGO) versus placebo after first-line (1L) platinum and fluoropyrimidines-based chemotherapy in HER2-negative advanced gastric (GC)/gastroesophageal junction (GEJ) cancer: Results of phase II randomized a-MANTRA study (GOIRC-05-2016)

6114 POSTER Clinical Outcomes of Bevacizumab (BV) + XELOX Combination for the First-line Treatment of Patients (pts) With Advanced Cancer of the Colon or Rectum (ACRC) – Preliminary Results of the OBELIX Study

6628 POSTER A Combination of RAD001 and Octreotide LAR as First-line Treatment of Well Differentiated Neuroendocrine Tumours – an I.T.M.O. (Italian Trials in Medical Oncology) Group Study

7117 Do circulating tumor cells (CTCs) correlate with response to first-line sunitinib in metastatic renal carcinoma?

795 Protein Pathway Activation Mapping of KRAS Mutated NSCLC Clinical Samples Reveals Systemic Pathway Alterations and Point to New Therapeutic Targets for EGFR Resistant Tumors

800TiP Meet-URO 12: A randomized phase II trial of niraparib versus best supportive care (BSC) as maintenance treatment in patients with locally advanced or metastatic urothelial cancer (UC) whose disease did not progress after completion of first-line platinum-based chemotherapy

837PPOOR RISK METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS ARE NOT A HOMOGENEOUS GROUP: A NEW STRATIFICATING MODEL IN THE ERA OF TARGETED THERAPY

854P - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)

854PUpdated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)

9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio

Abstract P1-13-02: Withdrawn

Abstract P5-12-05: 9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER

Advanced Oxidation Processes for Treating Groundwater Contaminated With TCE and PCE: Pilot-Scale Evaluations

Advanced oxidation processes for treating groundwater contaminated with TCE and PCE: pilot-scale evaluations

Advances in Hybrid Organic-Inorganic Proton Exchange Polymer Membranes Incorporating Heteropoly Acids

Application of mass-transfer theory to the kinetics of a fast gas-liquid reaction: chlorine hydrolysis

Applying infrared thermography as a quality-control tool for the rapid detection of polymer-electrolyte-membrane-fuel-cell catalyst-layer-thickness variations

Suchergebnisse filtern